Workflow
恒瑞医药(600276.SH):2025年中报净利润为44.50亿元

Financial Performance - The company reported a total revenue of 15.761 billion yuan for the first half of 2025 [1] - The net profit attributable to shareholders was 4.450 billion yuan [1] - The net cash inflow from operating activities was 4.300 billion yuan [1] Financial Ratios - The latest debt-to-asset ratio is 6.14% [3] - The gross profit margin stands at 86.58% [3] - The return on equity (ROE) is 7.61%, which is a decrease of 0.44 percentage points compared to the same period last year [3] Earnings and Efficiency Metrics - The diluted earnings per share (EPS) is 0.70 yuan [4] - The total asset turnover ratio is 0.28 times, a decrease of 0.02 times or 5.71% year-on-year [4] - The inventory turnover ratio is 0.85 times [4] Shareholder Information - The number of shareholders is 364,700, with the top ten shareholders holding 4.043 billion shares, accounting for 60.91% of the total share capital [4] - The largest shareholder is Jiangsu Hengrui Medicine Group Co., Ltd., holding 23.18% of the shares [4]